Health and Healthcare
CryoCor Regains Lost Ground; FDA Remains Unpredictable (CRYO)
Published:
CryoCor Inc. (CRYO-NASDAQ) is trading up almost 100% in early trading today. Last night the company announced that an FDA Advisory Panel had recommended backing the company’s pre-market approval application for the company’s treatment device for atrial flutter (ahead of the formal vote in August).
Back on June 25, all the way back to Monday, this stock took a beating. The FDA had posted its review stating that the device that uses extreme cold to treat defective heart muscle did not show overwhelmingly safe or effective results in company studies. Shares fell from $4.40 down to $2.77 at the close on Monday. Now shares are back up to $4.95.
This just goes to show how volatile and unpredictable the FDA can be. If you don’t believe that the FDA is becoming more and more unpredictable, go ask a certain maker of a last line of defense for prostate cancer about it. CryoCor has a 52-week trading range of $1.25 to $7.35, and its market cap based on a $4.95 price is only $60 Million.
Jon C. Ogg
June 28, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
The Average American Is Losing Their Savings Every Day (Sponsor)
If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4% today, and inflation is much higher. Checking accounts are even worse.
Every day you don’t move to a high-yield savings account that beats inflation, you lose more and more value.
But there is good news. To win qualified customers, some accounts are paying 9-10x this national average. That’s an incredible way to keep your money safe, and get paid at the same time. Our top pick for high yield savings accounts includes other one time cash bonuses, and is FDIC insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes and your money could be working for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
